Who are indacaterol maleate/mometasone furoate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salmeterol 50 mcg via DISKUS, Symbicort® Turbohaler® Inhalation Powder, Symbicort TBH - Turbuhaler, budesonide plus formoterol combination, Symbicort Turbohaler, Seretide Evohaler.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indacaterol-maleate-mometasone-furoate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

indacaterol maleate/mometasone furoate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

indacaterol maleate/mometasone furoate (indacaterol maleate/mometasone furoate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination. Area: Respiratory.

phase 3 Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

indacaterol maleate/mometasone furoate (indacaterol maleate/mometasone furoate) — Novartis. Indacaterol maleate is a long-acting beta2-adrenergic receptor agonist, while mometasone furoate is an inhaled corticosteroid.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
indacaterol maleate/mometasone furoate TARGET	indacaterol maleate/mometasone furoate	Novartis	phase 3	Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination	beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS	Salmeterol 50 mcg via DISKUS	GlaxoSmithKline	marketed	Long-acting beta2-adrenergic agonist (LABA)	Beta2-adrenergic receptors
Symbicort® Turbohaler® Inhalation Powder	Symbicort® Turbohaler® Inhalation Powder	Pearl Therapeutics, Inc.	phase 3	Inhaled corticosteroid/long-acting beta2-adrenergic agonist	Beta2-adrenergic receptor
Symbicort TBH - Turbuhaler	Symbicort TBH - Turbuhaler	AstraZeneca	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
budesonide plus formoterol combination	budesonide plus formoterol combination	Chiesi Farmaceutici S.p.A.	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
Symbicort Turbohaler	Symbicort Turbohaler	Pearl Therapeutics, Inc.	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
Seretide Evohaler	Seretide Evohaler	FLUIDDA nv	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination class)

GlaxoSmithKline · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). indacaterol maleate/mometasone furoate — Competitive Intelligence Brief. https://druglandscape.com/ci/indacaterol-maleate-mometasone-furoate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab